Physician profile
Hillary Raynes
NPI 1346231859
$2,863.06
in general payments reported to CMS, 2019-2025
22 companies · $1,330 in 2025
The $1,330 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $377 · 2021: $166 · 2022: $155 · 2023: $195 · 2024: $455 · 2025: $1,330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,448 · Travel and Lodging: $432 · Gift: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,447.83 |
| Travel and Lodging | $431.89 |
| Gift | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $929.92 | 2023-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Ucb, INC. | $445.83 | 2020-2025 | Nayzilam, Fintepla, Briviact |
| Neurelis, INC. | $231.88 | 2022-2025 | Valtoco |
| Tris Pharma INC | $161.77 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $146.84 | 2019-2020 | |
| Sk Life Science, INC. | $143.18 | 2020-2023 | |
| J2 Bio-Pharma LLC | $100.00 | 2024 | |
| Jazz Pharmaceuticals INC. | $90.34 | 2022-2025 | |
| Aquestive Therapeutics, INC. | $77.41 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $76.82 | 2024-2025 | Qelbree |
| Greenwich Biosciences, INC. | $65.54 | 2020-2021 | |
| Azurity Pharmaceuticals, INC. | $60.95 | 2023-2025 | Zonisade, Eprontia |
| Sunovion Pharmaceuticals INC. | $52.93 | 2019 | |
| Biomarin Pharmaceutical INC. | $49.65 | 2025 | Brineura |
| Biocodex, INC. | $39.51 | 2023-2025 | Diacomit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orchard Therapeutics North America | $37.92 | 2024 | Lenmeldy |
| Neos Therapeutics, Lp | $35.19 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $28.68 | 2025 | Dojolvi |
| Travere Therapeutics, INC. | $26.00 | 2019 | |
| Ironshore Pharmaceuticals INC. | $22.22 | 2024 | |
| Upsher-Smith Laboratories LLC | $21.02 | 2022 | |
| Eisai INC. | $19.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hillary Raynes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.